Skip to main content
SpringerLink
Log in
Book cover

Immune Mediators in Cancer pp 107–115Cite as

Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells

  • Protocol
  • First Online:

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2108))

Abstract

The pro-inflammatory and pro-angiogenic chemokine interleukin-8 (IL-8, CXCL8) induces proliferation and invasion of solid tumor cells. In many types of solid cancer, including triple-negative breast cancer (TNBC), the IL-8 expression is induced by proteasome inhibition. In this chapter, we describe a protocol for the analysis of TNBC cell invasion induced by IL-8 in response to proteasome inhibition by bortezomib (BZ). Using this approach, we show that BZ increases the invasion ability of TNBC cells, and that the BZ-increased TNBC cell invasion is suppressed by IκB kinase (IKK) inhibition, which also decreases the IL-8 expression. The experimental protocol includes the cell invasion assay, microscopic evaluation of the invading cells, and quantitative analysis of the obtained images. This protocol should be applicable also for measurement of chemokine-induced tumor cell invasion in other types of cancer cells.

This is a preview of subscription content, log in via an institution.

Protocol
USD   49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

References

  1. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735–6741

    Article  CAS  Google Scholar 

  2. Lazennec G, Richmond A (2010) Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16:133–144

    Article  CAS  Google Scholar 

  3. Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A et al (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22:256–265

    Article  CAS  Google Scholar 

  4. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C et al (2004) Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23:6105–6114

    Article  CAS  Google Scholar 

  5. Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L et al (2011) A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 13:R97

    Article  Google Scholar 

  6. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N et al (2013) Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73:3470–3480

    Article  CAS  Google Scholar 

  7. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071–3076

    CAS  PubMed  Google Scholar 

  8. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2005) Proteasome inhibition in the treatment of cancer. Cell Cycle 4:290–296

    Article  CAS  Google Scholar 

  9. Shah JJ, Orlowski RZ (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:1964–1979

    Article  CAS  Google Scholar 

  10. Kuhn DJ, Orlowski RZ (2012) The immunoproteasome as a target in hematologic malignancies. Semin Hematol 49:258–262

    Article  CAS  Google Scholar 

  11. McConkey DJ, Zhu K (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 11:164–179

    Article  CAS  Google Scholar 

  12. Chen YJ, Yeh MH, Yu MC, Wei YL, Chen WS, Chen JY et al (2013) Lapatinib-induced NFκB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Res 15:R108

    Article  Google Scholar 

  13. Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ et al (2013) A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell 24:182–196

    Article  CAS  Google Scholar 

  14. Deshmukh RR, Kim S, Elghoul Y, Dou QP (2017) P-glycoprotein inhibition sensitizes human breast cancer cells to proteasome inhibitors. J Cell Biochem 118:1239–1248

    Article  CAS  Google Scholar 

  15. Vu HY, Juvekar A, Ghosh C, Ramaswami S, Le DH, Vancurova I (2008) Proteasome inhibitors induce apoptosis of prostate cancer cells by inducing nuclear translocation of IκBα. Arch Biochem Biophys 475:156–163

    Article  CAS  Google Scholar 

  16. Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S et al (2013) Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. J Immunol 191:2837–2846

    Article  CAS  Google Scholar 

  17. Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V et al (2014) Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to IL-8 promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 289:2687–2700

    Article  CAS  Google Scholar 

  18. Uddin MM, Zou Y, Sharma T, Gatla HR, Vancurova I (2018) Proteasome inhibition induces IKK-dependent interleukin-8 expression in triple negative breast cancer cells: opportunity for combination therapy. PLoS One 13(8):e0201858. https://doi.org/10.1371/journal.pone.0201858

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by NIH grant CA202775 to I. Vancurova.

Author information

Authors and Affiliations

  1. Department of Biological Sciences, St. John’s University, Queens, NY, USA

    Mohammad M. Uddin, Bijaya Gaire, Betsy Deza & Ivana Vancurova

Authors
  1. Mohammad M. Uddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bijaya Gaire
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Betsy Deza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivana Vancurova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ivana Vancurova .

Editor information

Editors and Affiliations

  1. Department of Biological Sciences, St. John’s University, Queens, NY, USA

    Ivana Vancurova

  2. Department of Biological Sciences, St. John’s University, Queens, NY, USA

    Yan Zhu

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Uddin, M.M., Gaire, B., Deza, B., Vancurova, I. (2020). Interleukin-8-Induced Invasion Assay in Triple-Negative Breast Cancer Cells. In: Vancurova, I., Zhu, Y. (eds) Immune Mediators in Cancer. Methods in Molecular Biology, vol 2108. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0247-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0247-8_9

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0246-1

  • Online ISBN: 978-1-0716-0247-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation